AnGes, Inc. (AMGXF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
AnGes, Inc. (AMGXF) with AI Score 59/100 (Hold). AnGes, Inc. is a Japanese biopharmaceutical company focused on developing gene-based medical products. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026AnGes, Inc. (AMGXF) Healthcare & Pipeline Overview
AnGes, Inc., a biopharmaceutical firm based in Japan, specializes in gene-based therapies, notably HGF Plasmid for critical limb ischemia, and is expanding its pipeline through strategic alliances and collaborative research in areas like inflammation, dermatology, and vaccine development, operating within the competitive biotechnology sector.
Investment Thesis
AnGes, Inc. presents a high-risk, high-reward investment profile typical of early-stage biotechnology companies. The company's value is primarily tied to the successful development and commercialization of its gene-based therapies, particularly HGF Plasmid for critical limb ischemia. While the company has established partnerships with larger pharmaceutical firms, its financial performance is currently characterized by negative profitability, with a profit margin of -586.1%. Upcoming catalysts include clinical trial results for its pipeline products and potential regulatory approvals. The company's beta of 0.80 suggests lower volatility than the overall market. Investors should closely monitor clinical trial progress, regulatory decisions, and partnership developments to assess the company's long-term potential.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.14 billion reflects its position as a small-cap biotechnology company.
- Negative P/E ratio of -5.88 indicates the company is currently unprofitable.
- Gross margin of 36.7% suggests potential for profitability if sales volume increases.
- Profit margin of -586.1% highlights significant losses relative to revenue.
- Beta of 0.80 indicates lower volatility compared to the overall market.
Competitors & Peers
Strengths
- Proprietary gene therapy technology.
- Strategic partnerships with established pharmaceutical companies.
- Diverse pipeline of therapeutic candidates.
- Focus on unmet medical needs.
Weaknesses
- Limited financial resources.
- Dependence on partnerships for commercialization.
- High research and development costs.
- Negative profitability.
Catalysts
- Upcoming: Clinical trial results for HGF Plasmid for critical limb ischemia.
- Upcoming: Regulatory approval decisions for HGF Plasmid in Japan and the United States.
- Ongoing: Progress in the development of NF-kB Decoy Oligonucleotide for inflammatory diseases.
- Ongoing: Advancement of vaccine development programs, including the coronavirus vaccine.
- Ongoing: Potential for new strategic partnerships with pharmaceutical companies.
Risks
- Potential: Clinical trial failures for pipeline products.
- Potential: Regulatory rejection of HGF Plasmid or other therapies.
- Potential: Competition from established pharmaceutical companies.
- Ongoing: Limited financial resources and dependence on partnerships.
- Ongoing: High research and development costs.
Growth Opportunities
- HGF Plasmid Commercialization: The successful commercialization of HGF Plasmid for critical limb ischemia represents a significant growth opportunity. The market for treating peripheral arterial disease, which includes critical limb ischemia, is substantial and growing, driven by an aging population and increasing prevalence of diabetes. If approved, HGF Plasmid could capture a significant share of this market, generating substantial revenue for AnGes. The timeline for this growth opportunity depends on regulatory approval processes in Japan and the United States.
- NF-kB Decoy Oligonucleotide Development: The development of NF-kB Decoy Oligonucleotide for inflammatory diseases, including low back pain and atopic dermatitis, offers another avenue for growth. The market for anti-inflammatory drugs is large and diverse, with significant unmet needs. Successful clinical trials and regulatory approval could position AnGes as a key player in this market. The timeline for this growth opportunity depends on clinical trial outcomes and regulatory decisions.
- Vaccine Development Programs: AnGes's vaccine development programs, including the coronavirus vaccine and cervical intraepithelial neoplasia therapeutic vaccines, represent long-term growth opportunities. The global vaccine market is experiencing rapid growth, driven by the COVID-19 pandemic and increasing awareness of preventative healthcare. Successful development and commercialization of these vaccines could generate significant revenue for AnGes. The timeline for this growth opportunity depends on clinical trial results and regulatory approvals.
- Strategic Partnerships: AnGes's strategy of forming strategic partnerships with larger pharmaceutical companies provides access to resources, expertise, and distribution channels. These partnerships can accelerate the development and commercialization of its products, reducing risk and increasing the likelihood of success. The continued cultivation of these partnerships is crucial for AnGes's growth. The timeline for this growth opportunity is ongoing.
- Expansion into New Markets: AnGes has the opportunity to expand its geographic reach beyond Japan and the United States. Entering new markets, such as Europe and Asia, could significantly increase its revenue potential. This expansion would require significant investment in marketing, sales, and distribution infrastructure. The timeline for this growth opportunity depends on market research, regulatory approvals, and resource allocation.
Opportunities
- Successful commercialization of HGF Plasmid.
- Expansion into new markets.
- Development of new gene-based therapies.
- Increased demand for vaccines.
Threats
- Regulatory hurdles.
- Competition from established pharmaceutical companies.
- Clinical trial failures.
- Patent expirations.
Competitive Advantages
- Proprietary gene therapy technology.
- Strategic partnerships with established pharmaceutical companies.
- Pipeline of novel therapeutic candidates.
- Intellectual property protection through patents.
About AMGXF
Founded in 1999 and headquartered in Ibaraki, Japan, AnGes, Inc. is a biopharmaceutical company dedicated to the research and development of gene-based medical products. Originally named AnGes MG, Inc., the company rebranded in July 2017 to AnGes, Inc. Its primary focus is on Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy designed to treat critical limb ischemia, a condition characterized by severely restricted blood flow to the legs. Beyond HGF Plasmid, AnGes is actively developing a diverse pipeline of nucleic acid medicines, including NF-kB Decoy Oligonucleotide, aimed at suppressing inflammation in conditions like low back pain. The company is also pursuing treatments for atopic dermatitis and disc degeneration, as well as medical devices to prevent vascular restenosis. Further expanding its research scope, AnGes is developing cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer and DNA vaccines for high blood pressure in collaboration with Osaka University. AnGes strategically partners with other pharmaceutical companies. These alliances include collaborations with BioMarin Pharmaceutical Inc. to market Naglazyme for mucopolysaccharidosis VI in Japan and with Mitsubishi Tanabe Pharma Corporation to market HGF Plasmid for peripheral arterial disease in the United States and Japan. Additional partnerships include SHIONOGI & CO., LTD. for topical drugs containing NF-kB decoy oligonucleotide for skin diseases, Vical, Inc. for Allovectin in cancer treatment, and Brickell Biotech, Inc. for a coronavirus vaccine in the United States and South America.
What They Do
- Develop gene-based medical products.
- Research and develop gene therapy for critical limb ischemia.
- Develop nucleic acid medicines to suppress inflammation.
- Create drugs for treating atopic dermatitis and disc degeneration.
- Produce medical devices for the prevention of vascular restenosis.
- Develop therapeutic vaccines for cervical cancer.
- Research and develop DNA vaccines for high blood pressure.
- Collaborate with other companies and universities on research and development.
Business Model
- Research and development of gene-based therapies.
- Out-licensing and partnering with larger pharmaceutical companies for commercialization.
- Potential for direct sales of approved products in specific markets.
- Collaborative research agreements with universities and other institutions.
Industry Context
AnGes, Inc. operates within the biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential. The industry is driven by innovation in gene therapy, vaccine development, and personalized medicine. AnGes faces competition from established pharmaceutical companies and other biotechnology firms, including AAPGV, ADOCY, EKDHF, EPRXF, and FPHAF, all of whom are developing novel therapies. The success of AnGes depends on its ability to secure regulatory approvals, establish strategic partnerships, and effectively commercialize its products in a rapidly evolving market.
Key Customers
- Patients suffering from critical limb ischemia.
- Patients with inflammatory diseases.
- Patients with atopic dermatitis and disc degeneration.
- Hospitals and clinics.
- Pharmaceutical companies through licensing agreements.
Financials
Chart & Info
AnGes, Inc. (AMGXF) stock price: Price data unavailable
Latest News
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AMGXF.
Price Targets
Wall Street price target analysis for AMGXF.
MoonshotScore
What does this score mean?
The MoonshotScore rates AMGXF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Ei Yamada
Unknown
Information about Ei Yamada's background is not available in the provided data. His career history, education, and previous roles are currently unknown. Further research would be required to provide a comprehensive profile.
Track Record: Information about Ei Yamada's track record is not available in the provided data. Key achievements, strategic decisions, and company milestones under his leadership are currently unknown. Further research would be required to assess his performance.
AMGXF OTC Market Information
The OTC Other tier, where AnGes, Inc. (AMGXF) trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure and may not meet minimum listing requirements. This contrasts with exchanges like the NYSE or NASDAQ, which have stringent listing standards, including minimum share price, market capitalization, and financial reporting requirements. Investing in OTC Other stocks carries significantly higher risk due to the lack of transparency and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Low trading volume can lead to price volatility.
- Higher potential for fraud and manipulation.
- Lack of regulatory oversight increases investment risk.
- Going concern risk due to potential financial instability.
- Verify the company's registration and legal standing.
- Attempt to locate and review any available financial statements.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- Established partnerships with reputable pharmaceutical companies.
- Focus on research and development in a specialized area.
- History of operations since 1999.
- Development of products with potential medical benefits.
What Investors Ask About AnGes, Inc. (AMGXF)
What does AnGes, Inc. do?
AnGes, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of gene-based medical products. Its lead product is HGF Plasmid, a gene therapy designed to treat critical limb ischemia. The company also has a pipeline of other products in development, including nucleic acid medicines for inflammatory diseases, vaccines, and medical devices. AnGes collaborates with other pharmaceutical companies and universities to advance its research and development efforts.
What do analysts say about AMGXF stock?
AI analysis is pending for AMGXF. Generally, biotechnology stocks are viewed as high-risk, high-reward investments due to the lengthy and uncertain drug development process. Key valuation metrics for biotechnology companies include pipeline potential, clinical trial results, and regulatory approval prospects. Investors should carefully consider these factors before investing in AMGXF.
What are the main risks for AMGXF?
The main risks for AnGes, Inc. include clinical trial failures, regulatory rejection of its products, competition from established pharmaceutical companies, limited financial resources, and dependence on partnerships. As an OTC-listed company, AMGXF carries additional risks related to limited disclosure, low liquidity, and potential for manipulation. Investors should carefully assess these risks before investing.
What are the key factors to evaluate for AMGXF?
AnGes, Inc. (AMGXF) currently holds an AI score of 59/100, indicating moderate score. Key strength: Proprietary gene therapy technology.. Primary risk to monitor: Potential: Clinical trial failures for pipeline products.. This is not financial advice.
How frequently does AMGXF data refresh on this page?
AMGXF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AMGXF's recent stock price performance?
Recent price movement in AnGes, Inc. (AMGXF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary gene therapy technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider AMGXF overvalued or undervalued right now?
Determining whether AnGes, Inc. (AMGXF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying AMGXF?
Before investing in AnGes, Inc. (AMGXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be incomplete.
- AI analysis is pending and may provide further insights.